brevifoliol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 178222 |
| CHEMBL ID | 470498 |
| SCHEMBL ID | 43855 |
| MeSH ID | M0467670 |
| Synonym |
|---|
| brevifoliol |
| [(2s,4r,5r,5as,6s,8s,9ar,10as)-5,6-diacetyloxy-2,8-dihydroxy-10a-(2-hydroxypropan-2-yl)-3,5a-dimethyl-9-methylidene-2,4,5,6,7,8,9a,10-octahydro-1h-benzo[g]azulen-4-yl] benzoate |
| CHEMBL470498 |
| 134955-83-2 |
| 2-deacetoxytaxchinin a |
| benz(f)azulene-2,6,8,9,10(3h)-pentol, 2,4,4a,5,6,7,8,8a,9,10-decahydro-3a-(1-hydroxy-1-methylethyl)-1,8a-dimethyl-5-methylene-,8,9-diacetate 10-benzoate, (2s,3as,4ar,6s,8s,8as,9r,10r)- |
| SCHEMBL43855 |
| 8,9-bis(acetyloxy)-2,6-dihydroxy-3a-(2-hydroxypropan-2-yl)-1,8a-dimethyl-5-methylidene-2,3,3a,4,4a,5,6,7,8,8a,9,10-dodecahydrobenzo[f]azulen-10-yl benzoate |
| DTXSID40928835 |
Bevifoliol is a natural diterpene isolated from Taxus baccata Nutt. It has anti-tubercular potential against Mycobacterium tuberculosis H37Ra.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Brevifoliol is an abeo-taxane isolated from the Taxus wallichiana needles; eighteen semisynthetic esters derivatives of brevifoliol were prepared by Steglich esterification and screened for their anti-tubercular potential against Mycobacterium tuberculosis H37Ra avirulent strain. " | ( Brevifoliol and its Analogs: A New Class of Anti-tubercular Agents. Alam, S; Bhukya, B; Chaturvedi, V; Khan, F; Kumar, S; Negi, AS; Srivastava, SK; Trivedi, P, 2021) | 3.51 |
| "Brevifoliol is a natural diterpene isolated from Taxus baccata Nutt. " | ( Characterization of an abeo-taxane: brevifoliol and derivatives. Breau, L; Gunning, PJ; Soucy, C; Towers, N; Tremblay, S, 2004) | 2.04 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID371124 | Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Syntheses and cytotoxicities of the analogues of the taxoid brevifoliol. |
| AID371121 | Cytotoxicity against human KB cells after 48 hrs by MTT assay | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Syntheses and cytotoxicities of the analogues of the taxoid brevifoliol. |
| AID398248 | Cytotoxicity against human KB cells | 2004 | Journal of natural products, Feb, Volume: 67, Issue:2 | Biological activity and chemistry of taxoids from the Japanese yew, Taxus cuspidata. |
| AID371123 | Cytotoxicity against human Caco-2 cells after 48 hrs by MTT assay | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Syntheses and cytotoxicities of the analogues of the taxoid brevifoliol. |
| AID371122 | Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay | 2008 | European journal of medicinal chemistry, Jul, Volume: 43, Issue:7 | Syntheses and cytotoxicities of the analogues of the taxoid brevifoliol. |
| AID382274 | Cytotoxicity against human A459 cells after 72 hrs by sulforhodamine B assay | 2008 | Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9 | Synthesis, cytotoxic activity, and SAR analysis of the derivatives of taxchinin A and brevifoliol. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.70) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||